Merck Hyzaar blood pressure reduction is 50% greater than Cozaar alone; combo approved April 28.
Executive Summary
MERCK HYZAAR BLOOD PRESSURE REDUCTION IS 5.5/3.5 mmHg BETTER THAN COZAAR at the starting dose of the combination product, according to labeling approved by FDA April 28. The combination offers the potential for a 50% increase in blood pressure reduction compared to losartan alone, Merck said. The approval comes exactly two weeks after the agency's April 14 approval of Merck's Cozaar (losartan potassium tablets). Hyzaar is a combination of Cozaar and low-dose hydrochlorothiazide indicated for treatment of hypertension. Merck filed the Hyzaar NDA (20-387) on Dec. 10, 1993.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth